Neuropace
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $21,466 | $21,060 | $19,256 | $18,124 |
Gross Profit | 16,188 | 15,420 | 14,134 | 13,343 |
EBITDA | -2,607 | -2,819 | -4,904 | -6,244 |
EBIT | -3,058 | -3,270 | -5,348 | -6,667 |
Net Income | -5,250 | -5,452 | -7,514 | -8,925 |
Net Change In Cash | 21,466 | 21,060 | 19,256 | 18,124 |
Free Cash Flow | -4,836 | -1,824 | -3,963 | -7,632 |
Cash | 13,430 | 15,418 | 12,844 | 12,998 |
Basic Shares | 29,914 | 29,444 | 28,853 | 28,285 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $79,906 | $65,421 | $45,520 | $45,183 |
Gross Profit | 59,085 | 48,122 | 32,493 | 33,435 |
EBITDA | -16,574 | -22,834 | -36,566 | -28,374 |
EBIT | -18,343 | -24,439 | -39,553 | -28,670 |
Net Income | -27,141 | -32,956 | -53,370 | -38,109 |
Net Change In Cash | 79,906 | 65,421 | 45,520 | 45,183 |
Cost of Revenue | -12,582 | -7,447 | ||
Free Cash Flow | -17,949 | -19,874 | -37,472 | -24,961 |
Cash | 13,430 | 18,058 | 6,605 | 19,187 |
Basic Shares | 29,126 | 25,851 | 24,594 | 24,452 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.18 |
2024-09-30 | -$0.19 |
2024-06-30 | -$0.26 |
2024-03-31 | -$0.32 |
